APC Reporter Screening for Cytotoxic T Cell Epitope Discovery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods struggle to identify target antigens specific to T cells, such as cytotoxic T cells, which are crucial for developing effective immunotherapies and vaccines, due to the challenge of recognizing rare and low-frequency antigen interactions amidst complex mixtures.

Innovation Solution

The use of antigen presenting cells (APCs) engineered with exogenous nucleic acids encoding candidate antigens, molecular reporters of Granzyme B activity, and inhibitors of CAD-mediated DNA degradation, allowing for high-throughput detection and isolation of antigens recognized by cytotoxic lymphocytes, including cytotoxic T cells and NK cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional methods are used to identify target antigens, then the process is simpler, but the throughput is low and the discovery is biased

Engineering Contradiction:

Improvethroughput of antigen identificationVSAvoidcomplexity of detection system

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent segments the antigen identification process into distinct functional modules: APCs expressing candidate antigens, molecular reporters for detection, and inhibitors to maintain DNA integrity. This segmentation enables high-throughput screening while maintaining manageable system complexity through modular design

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces molecular reporters as intermediary elements that mediate between the antigen-lymphocyte interaction and the detection system. These reporters convert biological interactions into measurable signals, enabling high-throughput detection without directly complicating the antigen identification process

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If high-throughput detection is implemented, then productivity improves, but the device complexity increases

Engineering Contradiction:

Improvedetection throughputVSAvoidcomplexity of APC engineering

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent employs universal APC platforms that can be engineered to express multiple different candidate antigens. The APCs serve multiple functions: presenting antigens, containing molecular reporters, and resisting DNA degradation. This multi-functionality enables high-throughput detection without proportionally increasing system complexity

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent changes the biochemical parameters of the detection system by introducing inhibitors of CAD-mediated DNA degradation. This parameter change maintains DNA integrity during high-throughput processing, enabling robust detection without requiring overly complex error correction mechanisms

Inventive Principle:

Principle #35Parameter changes

3Measurement precision

If APCs are engineered with multiple components, then detection sensitivity improves, but the ease of manufacture decreases

Engineering Contradiction:

Improvesensitivity of antigen recognition detectionVSAvoidease of APC engineering

Core Design Contradiction:

Measurement precisionVSEase of manufacture

Solution Approach 1:

The patent applies preliminary action by pre-engineering APCs with all necessary components (antigen expression machinery, molecular reporters, and DNA protection mechanisms) before the detection process. This preliminary preparation enables sensitive detection while simplifying the actual manufacturing process, as the complex engineering is done once rather than repeatedly

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables the sensitive and robust identification of antigens recognized by cytotoxic lymphocytes, overcoming low throughput and biased discovery, and facilitating the recovery of presenting APCs and antigens, thereby enhancing the development of targeted therapies and vaccines.

Implementation Method 1

a molecular reporter of Granzyme B (GzB) activity; a fusion polypeptide comprising a GzB cleavage site (VGPD, SEQ ID NO: 1) linked to a detection molecule

Methodology Applied

Scientific EffectGranzyme B cleavage: Enzyme